Mezzion Pharma Co.,Ltd. announced a private placement of the 3rd bearer type interest part no guarantee subordinated convertible bond for gross proceeds of KRW 20,000,000,000 on November 12, 2021. The transaction included participation from Tiger 5-03 Hedge Fund, Tiger TRUST 3 Hedge Fund, Tiger MERIT 3 Hedge Fund, Tiger 5-13 Hedge Fund, Tiger BALANCE 3 Hedge Fund, Tiger CORE 3 Hedge Fund, Tiger ORIGIN 3 Hedge Fund, Tiger KOSDAQ Venture Mezzanine Focus 313 General Private Equity Trust for KRW 6,182,000,000, Tiger 5 Combo Hedge Fund, Tiger 5-11 Hedge Fund, Tiger 5-21 Hedge Fund, Tiger 5-31 Hedge Fund, Tiger STAR 1 Hedge Fund, Tiger GLORY 1 Hedge Fund, Tiger 5-41 Hedge Fund, Tiger 5-51 Hedge Fund, Tiger Curves 1 Hedge Fund, Tiger KOSDAQ Venture IDEAL 110 Hedge Fund, Tiger NEW ERA 1 Hedge Fund, Tiger ACE 1 Hedge Fund, Tiger KOSDAQ Venture DIFFERENCE 111 Hedge Fund, Tiger ONLY 1 Hedge Fund, Tiger MEANING 1 Hedge Fund, Tiger CONSTANT 1 Hedge Fund for KRW 7,774,000,000, Tiger 5-04 Hedge Fund, Tiger WISE ONE 4 Hedge Fund, Tiger 5-14 Hedge Fund, Tiger CLASSIC 4 Hedge Fund for KRW 1,087,000,000, Tiger 5-02 Hedge Fund, Tiger Gangnam 5-22 Hedge Fund, Tiger HNW 5-32 Hedge Fund, Tiger HNW 5-42 Hedge Fund, Tiger Friend 2 Hedge Fund, Tiger Family 2 Hedge Fund, Tiger CORPORATE 2 Hedge Fund, Tiger TRUE 2 Hedge Fund, Tiger GEAR UP 2 Hedge Fund, Tiger GEAR UP 12 Hedge Fund, Tiger BLUE 2 Hedge Fund, Tiger NEW 2 Hedge Fund for KRW 4,957,000,000. The transaction has been approved by board of directors of the company. The bonds will not be listed. The bonds will have coupon rate and maturity rate as 0. The bonds will mature at November 16, 2051. The bonds are 100% convertible into common shares at of the company at the conversion price of KRW 156,113 per share. The conversion period will start from November 17, 2022 till October 16, 2051. The transaction is expected to close on November 16, 2021.